Turja Chakrabarti, Clinical and Research Fellow at City of Hope, President and Founder at Pratit International, shared on LinkedIn:
“Honored to have presented at the 27th Annual International Lung Cancer Congress in Huntington Beach, CA, where I spoke on ‘Immunotherapy in Metastatic NSCLC: When to Use CTLA-4 Blockade?’
CTLA-4 blockade remains one of the most nuanced decisions in the immunotherapy landscape for advanced lung cancer, and it was a privilege to discuss a case and the evolving evidence with leaders in the field including Peters Solange.
A special thank you to my faculty mentor, Christine M. Lovly for her guidance, and to my colleagues at City of Hope.
Grateful for the opportunity to learn, contribute, and bring these insights back to our patients.”
Other articles about NSCLC on OncoDaily.
